论文部分内容阅读
Phosphoinositide-3-kinase(PI3K) has attracted vast attention as a promising target for cancer therapeutics because the deregulation of the PI3K/Akt/mTOR signaling pathway is frequently observed in a wide variety of human cancers.A series of indazole-based derivatives were prepared and optimized to provide the highly efficacious PI3K/mTOR inhibitor ZHY147.ZHY147 has shown good physical properties and PK parameters,low nanomolar potency against PI3Kα(IC50=21 nM) and mTOR(IC50=3.6 nM),and excellent inhibition of cell proliferation in human cancer cell lines such as Rh30(IC50=0.287 μM),U87MG(IC50=0.338 μM),A549(IC50=0.140 μM) and LNCap(IC50=0.131 μM).In addition,ZHY147 showed good in vivo efficacy in U87MG tumor xenograft model.